• Is potent and bactericidal
  • Covers the most common Gram-positive pathogens in ABSSSI
  • Is simple to use with two streamlined dosing regimens
  • Plasma concentrations stay far above the susceptibility breakpoint for both dose regimens for at least 14 days
  • Offers rapid resolution of fever and spread of erythema
  • Has a low incidence of adverse events and low potential for drug/drug interactions
  1. Xydalba SmPC
  2. Vena A, et al. EP0175, Early clinical experience with dalbavancin in a tertiary hospital of Madrid, Spain. 27th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID 2017), 22-25 April 2017, Vienna, Austria
  3. Data on file. Chicago, IL: Durata Therapeutics, Inc. 2014. FDA Briefing Presentation. Anti-infective Drugs Advisory Committee Meeting. March 31, 2014. NDA 21-883
  4. Pommerville JC. Alcamo’s Fundamentals of Microbiology. Sudbury, MA: Jones and Bartlet Publishers, LLC; 2014:99-132
  5. FDA. Guidance for Industry. Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment. October 2013. https://www.fda.gov/downloads/Drugs/Guidances/ucm071185.pdf; Accessed June 28, 2017
  6. Mendes RE et al. Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13). J Antimicrob Chemother. 2016 Jan;71(1):276-8
  7. FDA Briefing Presentation. Anti-infective Drugs Advisory Committee Meeting. March 31, 2014. NDA 21-883
  8. Boucher HW, et al. N Engl J Med. 2014;370:2169-79
  9. Cubicin SPC 05/05/2015
  10. Dunne MW, et al. Clinical Infectious Diseases. 2016;62(5):545–51
  11. Dunne MW, et al. Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of aandomized, comparative studies. Drug Safety. 2015
  12. Eells SJ, et al. Antimicrob Agents Chemotherapy 2016;60(5):2941-48
  13. Tatarkiewicz J, et al. New agents approved for treatment of acute staphylococcal skin infections. Archives of Medical Science : AMS. 2016;12(6):1327-36. doi:10.5114/aoms.2016.59838
  14. Chapman Ann LN. Outpatient parenteral antimicrobial therapy. BMJ. 2013;346:f1585
  15. Malabarba A & Goldstein BP. J Antimicrob Chemother. 2005;55 Suppl 2:ii15-20
  16. Biedenbach DJ, et al. Antimicrob Agents Chemother. 2009;53(3):1260-3
  17. Biedenbach DJ & Jones RN. Diagn Microbiol Infect Dis. 2009;64(2):177-84
  18. Rappo U, et al. J Glob Antimicrob Resist. 2019 Feb 20;17:60-65
  19. Gonzalez PL, et al. Drugs Context. 2018 Dec 11;7:212559.